SK7112001A3 - Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system - Google Patents

Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system Download PDF

Info

Publication number
SK7112001A3
SK7112001A3 SK711-2001A SK7112001A SK7112001A3 SK 7112001 A3 SK7112001 A3 SK 7112001A3 SK 7112001 A SK7112001 A SK 7112001A SK 7112001 A3 SK7112001 A3 SK 7112001A3
Authority
SK
Slovakia
Prior art keywords
azabicyclo
exo
ethyl
fluorophenyl
heptan
Prior art date
Application number
SK711-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Gerd Steiner
Rainer Munschauer
Gerhard Gross
Martin Traut
Liliane Unger
Hans-Jurgen Teschendorf
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of SK7112001A3 publication Critical patent/SK7112001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK711-2001A 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system SK7112001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19854147A DE19854147A1 (de) 1998-11-24 1998-11-24 Verwendung von N-substituierten Azabicycloalkan-Derivaten zur Verwendung bei der Bekämpfung der Cocainsucht
PCT/EP1999/008734 WO2000030639A1 (de) 1998-11-24 1999-11-12 Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems

Publications (1)

Publication Number Publication Date
SK7112001A3 true SK7112001A3 (en) 2001-12-03

Family

ID=7888824

Family Applications (1)

Application Number Title Priority Date Filing Date
SK711-2001A SK7112001A3 (en) 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system

Country Status (21)

Country Link
EP (1) EP1133293A1 (zh)
JP (1) JP2002530333A (zh)
KR (1) KR20010080535A (zh)
CN (1) CN1328455A (zh)
AR (1) AR021502A1 (zh)
AU (1) AU1775300A (zh)
BG (1) BG105549A (zh)
BR (1) BR9915589A (zh)
CA (1) CA2352526A1 (zh)
CZ (1) CZ20011796A3 (zh)
DE (1) DE19854147A1 (zh)
HK (1) HK1040933A1 (zh)
HR (1) HRP20010472A2 (zh)
HU (1) HUP0104416A3 (zh)
IL (1) IL143181A0 (zh)
NO (1) NO20012538L (zh)
PL (1) PL348758A1 (zh)
SK (1) SK7112001A3 (zh)
TR (1) TR200101476T2 (zh)
WO (1) WO2000030639A1 (zh)
ZA (1) ZA200103976B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1836183A2 (en) 2004-12-13 2007-09-26 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
GB0812310D0 (en) 2008-07-03 2008-08-13 Syngenta Ltd Novel herbicides
WO2014111837A1 (en) * 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004311A1 (en) * 1987-11-12 1989-05-18 American Home Products Corporation Polycyclicamines with psychotropic activity
DE4427648A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
DE4427647A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
WO2000030639A1 (de) 2000-06-02
AU1775300A (en) 2000-06-13
CZ20011796A3 (cs) 2002-05-15
ZA200103976B (en) 2002-05-16
DE19854147A1 (de) 2000-05-25
BR9915589A (pt) 2001-08-07
HK1040933A1 (zh) 2002-06-28
JP2002530333A (ja) 2002-09-17
PL348758A1 (en) 2002-06-03
HUP0104416A2 (hu) 2002-04-29
BG105549A (en) 2001-12-29
EP1133293A1 (de) 2001-09-19
IL143181A0 (en) 2002-04-21
HUP0104416A3 (en) 2002-11-28
NO20012538D0 (no) 2001-05-23
KR20010080535A (ko) 2001-08-22
TR200101476T2 (tr) 2001-10-22
AR021502A1 (es) 2002-07-24
HRP20010472A2 (en) 2003-04-30
CA2352526A1 (en) 2000-06-02
CN1328455A (zh) 2001-12-26
NO20012538L (no) 2001-07-04

Similar Documents

Publication Publication Date Title
ES2258251T3 (es) Reboxetina para tratar la fibromialgia y otros trastornos somatoformes.
Caliendo et al. Derivatives as 5HT1A receptor ligands-past and present
AU2001282734B2 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
KR20160005341A (ko) Ampk 활성인자 및 세로토닌성 제제를 포함하는 약학 조성물 및 이의 사용 방법
AU2001282734A1 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
RU2135503C1 (ru) N-замещенные производные 3-азабицикло (3.2.0)гептана или их соли с физиологически совместимыми кислотами
AU4008699A (en) Combination therapy for treatment of refractory depression
CN116437928A (zh) 用于预防、抑制或治疗伴随着过敏反应的症状的医药组合物
US20040048869A1 (en) Combination treatment for depression, anxiety and psychosis
US6818639B2 (en) Pharmaceutical combination formulation and method of treatment with the combination
SK7112001A3 (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
Steiner et al. D4/5-HT2A Receptor antagonists: LU-111995 and other potential new antipsychotics in development
WO1998037893A1 (fr) Antagoniste du recepteur dopaminergique d4
MXPA01005104A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
US20240000795A1 (en) Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators
Baudy Agents for the treatment of neurodegenerative diseases: July-December 1997
WO2006034788A1 (en) Combinations of n-(indolecarbonyl-)piperazine derivatives and serotonin reuptake inhibitors
PL197984B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku